Literature DB >> 11568988

Acceleration of lung disease in children with cystic fibrosis after Pseudomonas aeruginosa acquisition.

M R Kosorok1, L Zeng, S E West, M J Rock, M L Splaingard, A Laxova, C G Green, J Collins, P M Farrell.   

Abstract

As part of the ongoing Wisconsin Cystic Fibrosis (CF) Neonatal Screening Project, we had the unique opportunity to study the longitudinal relationship between Pseudomonas aeruginosa (Pa) acquisition and infection and developing lung disease in children with CF. The primary objective was to determine whether acquisition of Pa was associated with a measurable change in the progression of lung disease. Two outcome measures were used to study 56 patients who were diagnosed through newborn screening: 1) Wisconsin additive chest radiograph score (WCXR), based on the average of scores from a pulmonologist and a radiologist, and 2) the highest forced expired volume in 1 sec (FEV(1))/forced vital capacity (FVC) ratio. We used two measures of Pa acquisition: 1) time of first positive protocol-determined oropharyngeal (with cough) culture, and 2) the magnitude of antibody titer detected by ELISA assays, using as antigen a crude cell lysate, purified exotoxin A, or an elastase toxoid prepared from three Pa strains. Other predictor variables included age, pancreatic status, height-for age, and weight-for-age-percentiles. The best regression model for predicting changes in the WCXR included time to first positive culture and antibody titer for Pa elastase. Prior to Pa acquisition, WCXR worsened by 0.45 points/year (P > 0.25); after Pa acquisition, the rate of worsening increased significantly (P < 0.001) to 1.40 points/year. Each antibody titer level (log base 2) increased the score by 0.48 points (P < 0.001). The best regression model for predicting change in the FEV(1)/FVC included only time to first positive culture. Prior to Pa acquisition, the FEV(1)/FVC ratio declined by 1.29%/year; after Pa infection, the rate of decrease significantly accelerated to 1.81%/year (P = 0.001). Our data show that Pa acquisition is associated with declining pulmonary status in children with CF, and that this effect is probably gradual rather than precipitous. Because these patients were diagnosed and treated aggressively, our estimates of the effects of Pa acquisition may be conservative. We also conclude that the WCXR appears to be more sensitive than FEV(1)/FVC in detecting early changes in lung disease associated with CF. Copyright 2001 Wiley-Liss, Inc.

Entities:  

Mesh:

Year:  2001        PMID: 11568988     DOI: 10.1002/ppul.2009.abs

Source DB:  PubMed          Journal:  Pediatr Pulmonol        ISSN: 1099-0496


  125 in total

Review 1.  Atypical cystic fibrosis--diagnostic and management dilemmas.

Authors:  Colin Wallis
Journal:  J R Soc Med       Date:  2003       Impact factor: 5.344

Review 2.  Inhaled antibiotics in cystic fibrosis: what's new?

Authors:  Simon Langton Hewer
Journal:  J R Soc Med       Date:  2012-06       Impact factor: 5.344

3.  Initial Pseudomonas aeruginosa treatment failure is associated with exacerbations in cystic fibrosis.

Authors:  Nicole Mayer-Hamblett; Richard A Kronmal; Ronald L Gibson; Margaret Rosenfeld; George Retsch-Bogart; Miriam M Treggiari; Jane L Burns; Umer Khan; Bonnie W Ramsey
Journal:  Pediatr Pulmonol       Date:  2011-08-09

4.  Safety, efficacy and convenience of tobramycin inhalation powder in cystic fibrosis patients: The EAGER trial.

Authors:  Michael W Konstan; Patrick A Flume; Matthias Kappler; Raphaël Chiron; Mark Higgins; Florian Brockhaus; Jie Zhang; Gerhild Angyalosi; Ellie He; David E Geller
Journal:  J Cyst Fibros       Date:  2010-11-12       Impact factor: 5.482

5.  Genotypic diversity of Pseudomonas aeruginosa in cystic fibrosis siblings in Qatar using AFLP fingerprinting.

Authors:  A Abdul Wahab; S J Taj-Aldeen; F Hagen; S Diophode; A Saadoon; J F Meis; C H Klaassen
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2013-09-01       Impact factor: 3.267

6.  Standard versus biofilm antimicrobial susceptibility testing to guide antibiotic therapy in cystic fibrosis.

Authors:  Sherie Smith; Valerie Waters; Nikki Jahnke; Felix Ratjen
Journal:  Cochrane Database Syst Rev       Date:  2020-06-10

7.  Pulmonary function disparities exist and persist in Hispanic patients with cystic fibrosis: A longitudinal analysis.

Authors:  Meghan E McGarry; John M Neuhaus; Dennis W Nielson; Esteban Burchard; Ngoc P Ly
Journal:  Pediatr Pulmonol       Date:  2017-10-30

Review 8.  Accelerated Approval or Risk Reduction? How Response Biomarkers Advance Therapeutics through Clinical Trials in Cystic Fibrosis.

Authors:  N Mayer-Hamblett; D R VanDevanter
Journal:  Trends Mol Med       Date:  2020-08-28       Impact factor: 11.951

9.  Pseudomonas aeruginosa in vitro phenotypes distinguish cystic fibrosis infection stages and outcomes.

Authors:  Nicole Mayer-Hamblett; Margaret Rosenfeld; Ronald L Gibson; Bonnie W Ramsey; Hemantha D Kulasekara; George Z Retsch-Bogart; Wayne Morgan; Daniel J Wolter; Christopher E Pope; Laura S Houston; Bridget R Kulasekara; Umer Khan; Jane L Burns; Samuel I Miller; Lucas R Hoffman
Journal:  Am J Respir Crit Care Med       Date:  2014-08-01       Impact factor: 21.405

10.  Influenza-associated cystic fibrosis pulmonary exacerbations.

Authors:  Justin R Ortiz; Kathleen M Neuzil; John C Victor; Anna Wald; Moira L Aitken; Christopher H Goss
Journal:  Chest       Date:  2009-12-04       Impact factor: 9.410

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.